How Health Tech Works in the UK: A Guide for Founders Entering the Market
The UK Is Not the US With Pounds
Founders who've built health tech in the US often approach the UK as a straightforward localisation project: change the currency, adapt the privacy language for GDPR, and go. This is a significant mistake.
The UK health tech market has structural differences from the US that affect product strategy, go-to-market, regulatory requirements, and commercial model in fundamental ways.
The NHS as Both Customer and Context
The National Health Service is the dominant context for any UK health tech product. Even consumer health products operate in the shadow of the NHS — users compare your product's recommendations to what their GP told them, your pricing to NHS-provided alternatives, and your data practices to NHS data governance standards.
For products that want NHS as a customer (rather than just as context), the journey is through Integrated Care Systems (ICS), NHS procurement frameworks, and evidence requirements that go well beyond FDA-equivalent standards. NHS procurement moves slowly, requires clinical evidence, and prioritises interoperability with existing NHS systems.
DTAC and the Digital Technology Assessment Criteria
The Digital Technology Assessment Criteria (DTAC) is the NHS's baseline standard for digital health tools. If you want your product used in NHS settings, you need DTAC compliance. The criteria cover clinical safety, data protection, technical security, usability, and interoperability.
DTAC compliance is not as onerous as FDA clearance, but it's also not optional if you're targeting NHS organisations. Build it into your roadmap from day one rather than retrofitting it later.
The MHRA and Software as a Medical Device
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates Software as a Medical Device (SaMD) in the UK. Post-Brexit, the UK has its own regulatory pathway that diverges from the CE marking process used in the EU. If your product falls under SaMD classification, plan for an MHRA regulatory process that requires clinical evidence and pre-market review.
What UK Users Expect
UK health consumers are shaped by their experience of the NHS. They expect:
- Free or subsidised health services as the baseline — any premium health product needs to justify its cost against this baseline
- Data privacy as non-negotiable — UK users are generally more cautious about health data sharing than US users
- Clinical credibility — recommendations that conflict with NHS guidelines will face skepticism
- Long-term reliability — the reputation of health tech brands that raised money and disappeared has made UK users cautious about committing to new entrants
The Commercial Model Implications
The most successful UK health tech companies either sell directly to NHS organisations and employers (B2B), or they position as "NHS-plus" for consumers who want more than the NHS provides. Positioning against the NHS is strategically difficult and often counterproductive.
The B2B route is slower (NHS sales cycles are long) but creates durable revenue. The consumer route requires strong marketing and a clear value proposition that NHS provision genuinely doesn't address.
The Reputation Factor
Reputation in UK health tech is built slowly and lost quickly. The NICE endorsement process, NHS Digital certifications, and clinical guideline alignment all matter more in the UK than equivalent validation in other markets. Invest in the evidence base and the trust signals early — they compound over time and create barriers that are very difficult for new entrants to replicate.
